4. Clinical trials specifically designed for HPV-associated and HPV-independent endocervical adenocarcinoma patients are strongly encouraged to elucidate the predictive value of some biomarkers (ERBB2 PD-L1, and others). Trials combining unbalanced number of patients with adenocarcinoma (including HPV-independent disease) and squamous cell carcinoma may yield results not necessarily applicable to endocervical adenocarcinoma patients. The gene discussed is ERBB2; the disease is endocervical adenocarcinoma.